Immunovant halts IMVT-1402 cutaneous lupus program after phase 2 trial failure

Immunovant is halting development of its anti-FcRn antibody IMVT-1402 in cutaneous lupus erythematosus (CLE) after a Phase 2 proof-of-concept trial failed to meet its primary endpoint. The 57-patient study showed no statistically significant difference in CLASI-A scores at Week 12 compared to placebo. Despite favorable safety data and positive clinical trends linked to deeper IgG reductions, Immunovant cited a highly competitive landscape, which includes rival programs from Biogen, AstraZeneca, and Merck KGaA. Immunovant shares fell 6% on the news, though the company's other pipeline timelines remain on track.

Discontinuation of the lupus program

• ▪Immunovant decided to stop development of IMVT-1402 in cutaneous lupus erythematosus due to the clinical results observed and the competitive landscape.
• ▪Immunovant announced on September 23, 2026, that its Phase 2 trial of IMVT-1402 in cutaneous lupus erythematosus did not achieve statistical significance on the primary endpoint of percent change from baseline in the CLASI-A score at Week 12.

Clinical findings from the trial

• ▪IMVT-1402 demonstrated a favorable safety and tolerability profile in the cutaneous lupus erythematosus trial, consistent with prior studies.
• ▪Numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints in the cutaneous lupus erythematosus trial.
• ▪Patients in the IMVT-1402 trial who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses.

Cutaneous lupus trial design

• ▪Patients in Period 1 of the IMVT-1402 trial were randomized to receive either IMVT-1402 or a placebo for a 12-week treatment period.
• ▪The randomized, double-blind, placebo-controlled trial of IMVT-1402 in cutaneous lupus erythematosus enrolled 57 adult patients.

Immunovant stock performance

• ▪Immunovant shares closed at $37.29 on September 22, 2026, before falling in premarket trading on September 23, 2026.
• ▪Immunovant shares fell 6% to $35 in premarket trading on September 23, 2026, following the announcement of the trial failure.

Guggenheim analyst commentary

• ▪Guggenheim Securities analysts were cautious on the trial readout after Immunovant executives previously characterized the study as a fact-finding proof-of-concept in a competitive landscape.
• ▪Guggenheim Securities analysts detailed their caution regarding the trial readout in a note sent to investors in the month prior to the announcement.

Future development of IMVT-1402

• ▪Immunovant stated that all other clinical development timelines for IMVT-1402 remain on track following the cutaneous lupus erythematosus trial failure.
• ▪Immunovant is continuing to develop IMVT-1402 for Graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogren's disease.

Competitive landscape in lupus

• ▪Biogen reported a midphase win for its anti-BDCA2 antibody litifilimab in cutaneous lupus erythematosus in March 2026.
• ▪Johnson & Johnson reported a Phase 2 win for its FcRn blocker nipocalimab in systemic lupus erythematosus in January 2026.
• ▪Beeline is preparing to advance its oral TLR7/8 inhibitor into Phase 3 clinical trials for cutaneous lupus erythematosus.
• ▪AstraZeneca and Germany's Merck KGaA are running Phase 3 trials in cutaneous lupus erythematosus for a type I interferon receptor inhibitor and a TLR7/8 inhibitor, respectively.

Immunovant leadership and structure

• ▪Eric Venker, the Chief Executive Officer of Immunovant, thanked the patients and investigators who participated in the cutaneous lupus erythematosus study.
• ▪Immunovant is a clinical-stage immunology company and a majority-owned subsidiary of Roivant.

Debatable claims

• ▪FcRn inhibition remains a viable therapeutic approach for cutaneous lupus
• ▪Immunovant should have continued developing IMVT-1402 for cutaneous lupus
• ▪The cutaneous lupus trial failure undermines the outlook for IMVT-1402 in other indications